Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

132 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Myrtleciclib, a CDK4/6/9 Inhibitor for the Treatment of Aggressive Cancers.
De Forni D, Poddesu B, Cugia G, Bonelli M, Galetti M, Petronini P, Lagacé L, Chafouleas J, Lori F. De Forni D, et al. Among authors: galetti m. Curr Med Chem. 2024 Sep 2. doi: 10.2174/0109298673298434240821101457. Online ahead of print. Curr Med Chem. 2024. PMID: 39225211
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer.
Galvani E, Alfieri R, Giovannetti E, Cavazzoni A, La Monica S, Galetti M, Fumarola C, Bonelli M, Mor M, Tiseo M, Peters GJ, Petronini PG, Ardizzoni A. Galvani E, et al. Among authors: galetti m. Curr Pharm Des. 2013;19(5):818-32. Curr Pharm Des. 2013. PMID: 22973953 Review.
Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines.
Digiacomo G, Fumarola C, La Monica S, Bonelli MA, Cretella D, Alfieri R, Cavazzoni A, Galetti M, Bertolini P, Missale G, Petronini PG. Digiacomo G, et al. Among authors: galetti m. Front Oncol. 2020 Sep 23;10:563249. doi: 10.3389/fonc.2020.563249. eCollection 2020. Front Oncol. 2020. PMID: 33072590 Free PMC article.
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells.
Digiacomo G, Fumarola C, La Monica S, Bonelli M, Cavazzoni A, Galetti M, Terenziani R, Eltayeb K, Volta F, Zoppi S, Bertolini P, Missale G, Alfieri R, Petronini PG. Digiacomo G, et al. Among authors: galetti m. Front Oncol. 2022 Jul 22;12:942341. doi: 10.3389/fonc.2022.942341. eCollection 2022. Front Oncol. 2022. PMID: 35936714 Free PMC article.
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC).
Cavazzoni A, Digiacomo G, Volta F, Alfieri R, Giovannetti E, Gnetti L, Bellini L, Galetti M, Fumarola C, Xu G, Bonelli M, La Monica S, Verzè M, Leonetti A, Eltayeb K, D'Agnelli S, Moron Dalla Tor L, Minari R, Petronini PG, Tiseo M. Cavazzoni A, et al. Among authors: galetti m. Lung Cancer. 2024 Jan;187:107438. doi: 10.1016/j.lungcan.2023.107438. Epub 2023 Dec 12. Lung Cancer. 2024. PMID: 38100954 Free article.
132 results